Fluorodopa (18F)
Chemical compound
Fluorodopa (18F), also known as FDOPA, is a fluorinated form of L-DOPA primarily synthesized as its fluorine-18 isotopologue for use as a radiotracer in positron emission tomography (PET).
The most common side effects are injection site pain.
01Medical uses
Fluorodopa (18F) is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adults with suspected Parkinsonian syndromes.
02History
In October 2019, Fluorodopa (18F) was approved in the United States for the visual detection of certain nerve cells in adults with suspected Parkinsonian syndromes.
The US Food and Drug Administration approved Fluorodopa F 18 based on evidence from one clinical trial of 56 participants with suspected Parkinsonian syndromes. The trial was conducted at one clinical site in the United States.
Sources and credits
This article is adapted from the Wikipedia article “Fluorodopa (18F)”, written by its contributors and licensed under CC BY-SA 4.0. Fathomly has changed the layout, removed citation markers, navigation and maintenance notices, and adjusted punctuation. This adapted version is shared under the same license. For references, see the original article.
Images, from Wikimedia Commons:
- Fluorodopa F-18.svg by User:Innerstream, Public domain
Fathomly is not affiliated with or endorsed by the Wikimedia Foundation. Spotted a problem? Tell us.